Albany Molecular Research Inc. Securities Litigation
On or around 01/02/2018 (Other)
Filing Date: July 11, 2017
According to the Complaint, on June 5, 2017, the Board caused the Company to enter into an agreement and plan of merger (“Merger Agreement”), pursuant to which each share of common stock of Albany will be converted into the right to receive $21.75 in cash (the “Merger Consideration”).
The Complaint alleges that on July 3, 2017, in order to convince Albany stockholders to vote in favor of the Proposed Merger, the Board authorized the filing of a materially incomplete and misleading Preliminary Proxy Statement (the “Proxy”) with the Securities and Exchange Commission (“SEC”), in violation of Sections 14(a) and 20(a) of the Exchange Act.
The first identified case was voluntarily dismissed on October 25, 2017.
A related action was filed in the Northern District of New York and docketed under 17-CV-01179.
On December 29, 2017, Plaintiff filed a Notice of Voluntary Dismissal.
Company & Securities Information
Defendant: Albany Molecular Research Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: AMRI
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Michael Eyre, et al. v. Albany Molecular Research Inc., et al.